Forum Agenda

July 23, Morning

The Evolution and Beyond of NewCo Session

Stay tuned

Planners
Jielun Zhu: Partner, NewCo Capital
Jie Wu: Head of Asia Pacific, MPM BioImpact / CBO, K2

 

Recent Trends and Future Outlook of NewCo Transactions
Eric Liu: Locust Walk China Head

 

Key Decisions in the Third Generation Evolution of NewCos and What Lies Ahead
Bella Chen: Partner, JunHe LLP

 

TBD
王宁玲: Managing Partner, Shanghai Office of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

 

Roundtable 1: Review, Iteration, and Evolution of the NewCo Model
Jie Wu (Moderator): Head of APAC, MPM BioImpact
Howard Liang: Ex-CFO & Chief Strategy Officer of BeOne (BeiGene); Ex-CFO & President of Tessera Therapeutics
Weidong Liu: Managing Director, Vivo Capital
Mark Tang: Chairman, World Biotech Capital LLC
Pony: CEO & Executive Director, VISEN Pharmaceuticals

 

Roundtable 2: NewCo's Exit and Related Challenges
Jielun Zhu (Moderator): Partner, NewCo Capital
Nisa Leung: Managing Partner, Aulis Capital
Zhui Chen: Founder and CEO, OTR Therapeutics
Hua Jiang: Executive Director, External Innovation & Partnership, BeOne
Ke Geng: Partner, O'Melveny & Myers